Skip to main content
    P

    Pelthos Therapeutics Inc. (PTHS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $9.40
    -7.14 (-43.17%)

    Market Cap: $36.96M

    Last updated: Oct 30, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    29%(2/7)
    Avg Surprise
    -137.51%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-3.33
    Range$-4.60 - $-1.60
    3 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-1.89-76.0%
    60d ago$-3.34+0.3%
    30d ago$-3.34+0.3%
    7d ago$-3.06-8.7%
    Current$-3.33
    Revenue Consensus
    $17M
    Range$12M - $21M
    7 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-8.16
    Range$-17.59 - $-2.54
    3 analysts
    Revenue Consensus
    $20M
    Range$10M - $30M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-8.16---
    Sep 26EST
    		-$-3.33---
    Jun 26
    Reported Aug 13
    		$-6.62$-3.02-119.21%Miss-23.0%
    Mar 26
    Reported May 14
    		$-4.66$-3.58-30.24%Miss-45.2%
    Dec 25
    Reported Mar 19
    		$-2.69$-4.18+35.65%Beat-740.6%
    Sep 25
    Reported Nov 13
    		$-5.30$-0.57-829.82%Miss-82.8%
    Jun 25
    Reported Aug 13
    		$-5.38$-6.26+14.06%Beat-73.5%
    Mar 25
    Reported May 28
    		$-3.21N/AN/ABeat+41.6%
    Dec 24
    Reported Feb 26
    		$-0.32$0.00N/AMiss-
    Sep 24
    Reported Nov 13
    		$-2.90$-2.30-26.09%Miss-
    Jun 24
    Reported Aug 13
    		$-3.10$-2.90-6.90%Miss-
    Mar 24
    Reported May 29
    		$-5.50N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.49EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-199.50%Operating Margin-101.40%
    ROE-333.80%ROIC-95.75%
    Financial Health
    Debt/Equity-46.58xInterest Coverage-9.61x
    Current Ratio1.98xQuick Ratio1.31x
    Trading Statistics
    Beta3.11Avg Volume63.41K
    52-Week High$37.5052-Week Low$9.02

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$16.74
    SMA 20$18.59
    SMA 50$21.36
    SMA 200$24.19
    EMA 10$15.91
    EMA 20$17.83
    EMA 50$20.71
    EMA 200$23.58

    MACD

    Line: -2.20Signal: -1.50Hist: -0.70

    ADX

    ADX: 27.6+DI: 10.5-DI: 41.6

    Aroon & PSAR

    Aroon Up36.0
    Aroon Down100.0
    PSAR$9.02

    Bollinger Bands

    Upper Band$24.61
    Lower Band$12.58
    %B Position6468%(Upper)
    Band Width-0.26

    RSI (14-Day)

    Oversold
    21.8

    Momentum Oscillators

    Stoch %K21.0
    Stoch %D16.4
    Williams %R-96.8
    ROC (10d)-53.3%
    Momentum-10.75
    CCI (20d)-194.0
    MFI (14d)40.6

    Volatility Measures

    ATR (14d)$2.18(23.2%)
    StdDev (20d)3.01
    Hist Vol172.8%(High)

    Volume Flow

    VWAP$12.97
    OBV3.0M
    AD Line551.6M
    CMF (20d)-0.559

    Volume Metrics

    Avg Vol (20d)66.4K
    Vol Ratio3.6x(High)
    VWMA (20d)$17.43

    Pivot Points

    R3$18.55
    R2$17.81
    R1$17.17
    Pivot Point$16.43
    S1$15.79
    S2$15.05
    S3$14.41

    Advanced Oscillators

    TSI-39.64
    Ultimate Osc18.6
    KST-220.28

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$15.60M$10.91M$9.39M$7.41M$0$0$-3,527$0$3,527$0N/A$0
    Cost of Revenue$3.61M$1.67M$1.67M$2.32M$0$0N/A$0$0$0N/A$0
    Gross Profit$11.99M$9.23M$7.72M$5.09M$0$0$-3,527$0$3,527$0N/A$0
    Operating Expenses$29.32M$22.32M$19.72M$20.45M$3.23M$1.83M$1.82M$2.05M$1.76M$1.93M$3.88M$1.29M
    R&D$600,000$186,000$373,888$145,000$515,000$194,000$284,439$415,000$12,955$466,606$2.29M$49,132
    SG&A$27.67M$21.10M$18.47M$19.63M$2.72M$1.64M$1.54M$1.63M$1.75M$1.47M$1.58M$1.24M
    Operating Income$-17,323,000$-13,088,000$-12,003,600$-15,362,000$-3,231,000$-1,834,000$-1,823,932$-2,049,000$-1,764,086$-1,933,982$-3,878,815$-1,291,726
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$2.39M$2.35M$16.58M$1.35M$218,000$134,000$102,119$39,000$7,533$628,348$160,338$130,006
    Income Before Tax$-23,417,000$-25,073,000$-28,586,450$-16,703,000$-3,449,000$-1,968,000$-1,926,051$-1,695,000$-1,771,619$-2,562,330$-4,039,153$-1,421,732
    Income Tax Expense$0$0$-6,922,000$-465,000$0$0$0$0$0$0$0$0
    Net Income$-23,417,000$-25,073,000$-21,664,450$-16,238,000$-3,449,000$-1,968,000$-1,926,051$-1,695,000$-1,771,619$-2,562,330$-4,039,153$-1,421,732
    EBITDA$-19,402,000$-20,955,000$-10,786,600$-14,603,891$-3,066,000$-1,740,000$-1,747,932$-1,645,630$-1,764,086$-1,328,352$-3,757,482$-1,274,062
    EBIT$-21,028,000$-22,720,000$-12,003,600$-15,357,000$-3,231,000$-1,834,000$-1,823,932$-1,656,000$-1,764,086$-1,933,982$-3,878,815$-1,291,726
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PTHS

    News

    No news available

    Company news will appear here when available

    PTHS Valuation and Fair Value

    P/E
    -0.5x
    P/B
    -22.2x
    See GNG's fair value

    PTHS Profitability: Margins, ROIC and FCF

    Gross margin
    78.6%
    Operating margin
    -101.4%
    Net margin
    -199.5%
    ROIC
    -95.8%
    ROE
    -333.8%

    PTHS Competitors

    CompanyTicker
    Elutia Inc.ELUT
    Rapid Micro Biosystems IncRPID
    Veru IncVERU
    Tela Bio IncTELA
    Scynexis IncSCYX
    Star Equity Holdings IncSTRR
    CVRx IncCVRX
    Generation Bio CoGBIO

    Sector: Healthcare

    PTHS Analyst Ratings

    Consensus
    Buy
    Analysts
    7
    Strong Buy
    1
    Buy
    6
    Hold
    0
    Sell
    0
    Strong Sell
    0

    PTHS Bull Case vs Bear Case

    Bull case

    • 100.0% of PTHS's analyst ratings are Buy or Strong Buy.

    Bear case

    • PTHS has a -199.5% net profit margin.
    • PTHS beat EPS estimates in 25.0% of its last 8 reported quarters.

    PTHS Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -137.5%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-3.33
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    Frequently Asked Questions About PTHS

    Does PTHS pay dividends?

    Pelthos Therapeutics Inc. (PTHS) does not currently pay a regular dividend.

    What is PTHS's market cap?

    Pelthos Therapeutics Inc. (PTHS) has a market capitalization of $36.96M with a current stock price of $9.40.

    Related stocks

    Sector: Healthcare

    All stocks starting with P

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In